Termination of Ultragenyx’s UX053 Phase I/II study is a minor setback for mRNA therapeutics:…
UX053 was one of five non-vaccine mRNA therapeutics in clinical trial development. The other four are all currently in Phase I/II…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.